- Home
- CHRS vs SGC Comparison
CHRS vs SGC Comparison
Compare CHRS & SGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRS | SGC |
|---|---|---|
| Founded | 2010 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0M | 168.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHRS | SGC |
|---|---|---|
| Price | $2.01 | $10.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.51 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 3.3M | 45.7K |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 5.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.34 | 0.36 |
| Revenue | $277,728,000.00 | ★ $565,017,000.00 |
| Revenue This Year | N/A | $0.73 |
| Revenue Next Year | $79.66 | $3.38 |
| P/E Ratio | ★ $1.53 | $29.03 |
| Revenue Growth | ★ 152.07 | N/A |
| 52 Week Low | $0.71 | $8.30 |
| 52 Week High | $2.62 | $15.31 |
Technical Indicators
Market Signals| Indicator | CHRS | SGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 57.87 |
| Support Level | $1.97 | $9.24 |
| Resistance Level | $2.20 | $10.95 |
| Average True Range (ATR) | 0.23 | 0.38 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 8.39 | 65.45 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.